Features of the Incidence and Management of Atrial Fibrillation in Normal Thyroid Function and Subclinical Functional Disorders and Associated Pathologies
DOI:
https://doi.org/10.61788/njn.v2i20.05Keywords:
atrial fibrillation, comorbidity, CHA 2 DS 2 VAScAbstract
Atrial fibrillation (AF) is the most common and serious complicated supraventricular arrhythmia. The presence of comorbidities during AF aggravates the course of this arrhythmia, increasing the risk of death and disability. The presented article provides information on the detection of comorbid cases associated with AF. The results show that 58.5% of patients had arterial hypertension along with AF, 78.7% had heart failure, 12.1% had DMT2, and 9.1% had metabolic syndrome. A combination of the above pathologies was found in some of the patients we examined. Thus, in the majority of patients, 2 comorbid pathologies (combination of AH and HF - 39.4%, combination of HF and DMT2 - 4.04%), and in 8.08% simultaneously 3 comorbidities (AH, HF and DMT2) were identified.
References
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS // European Heart Journal (2016) 37, 2893-2962, doi:10.1093/eurheartj/ehw210.
Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study // Stroke 2013;44:3103-3108.
Haim M, Hoshen M, Reges O et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non- valvular atrial fibrillation // J Am Heart Assoc 2015;4:e001486.
Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective // Clin Epidemiol 2014;6:213-220.
Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial // Eur Heart J 2004;25:1385-1394.
Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’ // Eur Heart J 2009;30:2969-2977.
Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan RT, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study // J Am Coll Cardiol 2014;64:2222-2231.
Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial // JAMA 2013;310:2050-2060.
Carroll K, Majeed A. Comorbidity associated with atrial fibrillation: a general practice- based study // British Journal of General Practice, November 2001, p. 884-891.
2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) // European Heart Journal, Volume 39, Issue 33, 01 September 2018, Pages 3021-3104, https://doi.org/10.1093/eurheartj/ehy339.
Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes - 2020, American Diabetes Association // Diabetes Care 2020 Jan; 43 (Supplement 1): S14-S31.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) // European Heart Journal (2016) 37, 2129-2200, doi:10.1093/eurheartj/ehw128.
Grundy S.M., Cleeman J.I., Daniels S.R. et al. Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary // Circulation. 2005;112:e285-e290.
Ellervik C., Roselli C., Christophersen I.E., et al. Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation, A Mendelian Randomization Study // JAMA Cardiol., 2019;4(2):144-152. doi:10.1001/ jamacardio.2018.4635.
Selmer C, Olesen JB, Hansen ML et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study // BMJ. 2012;345:e7895.
Kishore A, Vail A, Majid A, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis // Stroke 2014;45:520-526.
Henriksson KM, Farahmand B, Asberg S, et al. Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke // Int J Stroke 2012; 7:276-281.
Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72- hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study // Stroke 2013;44:3357-3364.
Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial // Eur Heart J 2004;25:1385-1394.
Hindricks G, Piorkowski C, Tanner H, et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence // Circulation 2005;112:307-313.
Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis // Lancet 2014;384:2235-2243.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study // Stroke 1991;22:983-988.
Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study // Am J Med 1995;98:476-484.
Manolis AJ, Rosei EA, Coca A, Cifkova R, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension // J Hypertens, 2012;30:239-252. 2
Guha K, McDonagh T. Heart failure epidemiology: European perspective // Curr Cardiol Rev., 2013;9:123-127.
Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? // Europace 2011;13:ii13-17.
Nerheim P., Birger-Botkin S., Piracha L., Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia // Circulation., 110 (2004), pp. 247-252.
Cleland J.G.F. et al. Beta-blockers for Heart Failure With Reduced, Mid-range, and Preserved Ejection Fraction.,An Individual Patient-level Analysis of Double-blind Randomized Trials // Eur Heart J. 2018;39(1):26-35.
Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women // J Am Coll Cardiol 2012;60:1421-1428.
Du X, Ninomiya T, de Galan B, Abadir E et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study // Eur Heart J., 2009;30:1128-1135.
Rizzo MR, Sasso FC, Marfella R, et al. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes // J Diabetes Complications 2015;29:88-92.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 National Association of Neurologists
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
